Seth A Hollander1, Ryan S Cantor2, Scott M Sutherland3, Devin A Koehl2, Elizabeth Pruitt2, Nancy McDonald4, James K Kirklin2, William J Ravekes5, Rebecca Ameduri6, Maryanne Chrisant7, Timothy M Hoffman8, Irene D Lytrivi9, Jennifer Conway10. 1. Department of Pediatrics (Cardiology), Stanford University School of Medicine, Palo Alto, California. 2. Kirklin Institute for Research in Surgical Outcomes, University of Alabama at Birmingham, Birmingham, Alabama. 3. Department of Pediatrics (Nephrology), Stanford University School of Medicine, Palo Alto, California. 4. Solid Organ Transplant Services, Lucile Packard Children's Hospital Stanford, Palo Alto, California. 5. Johns Hopkins School of Medicine, Baltimore, Maryland. 6. University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota. 7. Joe DiMaggio Children's Hospital, Hollywood, Florida. 8. University of North Carolina, Chapel Hill, North Carolina. 9. The Mount Sinai Medical Center, New York, New York. 10. University of Alberta, Edmonton, Alberta, Canada.
Abstract
BACKGROUND: The use of ventricular assist devices (VADs) in children with heart failure may be of particular benefit to those with accompanying renal failure, as improved renal function is seen in some, but not all recipients. We hypothesized that persistent renal dysfunction at 7 days and/or 1 month after VAD implantation would predict chronic kidney disease (CKD) 1 year after heart transplantation (HT). METHODS: Linkage analysis of all VAD patients enrolled in both the PEDIMACS and PHTS registries between 2012 and 2016. Persistent acute kidney injury (P-AKI), defined as a serum creatinine ≥1.5× baseline, was assessed at post-implant day 7. Estimated glomerular filtration rate (eGFR) was determined at implant, 30 days thereafter, and 12 months post-HT. Pre-implant eGFR, eGFR normalization (to ≥90 mL/min/1.73 m2 ), and P-AKI were used to predict post-HT CKD (eGFR <90 mL/min/1.73 m2 ). RESULTS: The mean implant eGFR was 85.4 ± 46.5 mL/min/1.73 m2 . P-AKI was present in 19/188 (10%). Mean eGFR at 1 month post-VAD implant was 131.1 ± 62.1 mL/min/1.73 m2 , significantly increased above baseline (P < 0.001). At 1 year post-HT (n = 133), 60 (45%) had CKD. Lower pre-implant eGFR was associated with post-HT CKD (OR 0.99, CI: 0.97-0.99, P = 0.005); P-AKI was not (OR 0.96, CI: 0.3-3.0, P = 0.9). Failure to normalize renal function 30 days after implant was highly associated with CKD at 1 year post-transplant (OR 12.5, CI 2.8-55, P = 0.003). CONCLUSIONS: Renal function improves after VAD implantation. Lower pre-implant eGFR and failure to normalize renal function during the support period are risk factors for CKD development after HT.
BACKGROUND: The use of ventricular assist devices (VADs) in children with heart failure may be of particular benefit to those with accompanying renal failure, as improved renal function is seen in some, but not all recipients. We hypothesized that persistent renal dysfunction at 7 days and/or 1 month after VAD implantation would predict chronic kidney disease (CKD) 1 year after heart transplantation (HT). METHODS: Linkage analysis of all VAD patients enrolled in both the PEDIMACS and PHTS registries between 2012 and 2016. Persistent acute kidney injury (P-AKI), defined as a serum creatinine ≥1.5× baseline, was assessed at post-implant day 7. Estimated glomerular filtration rate (eGFR) was determined at implant, 30 days thereafter, and 12 months post-HT. Pre-implant eGFR, eGFR normalization (to ≥90 mL/min/1.73 m2 ), and P-AKI were used to predict post-HT CKD (eGFR <90 mL/min/1.73 m2 ). RESULTS: The mean implant eGFR was 85.4 ± 46.5 mL/min/1.73 m2 . P-AKI was present in 19/188 (10%). Mean eGFR at 1 month post-VAD implant was 131.1 ± 62.1 mL/min/1.73 m2 , significantly increased above baseline (P < 0.001). At 1 year post-HT (n = 133), 60 (45%) had CKD. Lower pre-implant eGFR was associated with post-HT CKD (OR 0.99, CI: 0.97-0.99, P = 0.005); P-AKI was not (OR 0.96, CI: 0.3-3.0, P = 0.9). Failure to normalize renal function 30 days after implant was highly associated with CKD at 1 year post-transplant (OR 12.5, CI 2.8-55, P = 0.003). CONCLUSIONS: Renal function improves after VAD implantation. Lower pre-implant eGFR and failure to normalize renal function during the support period are risk factors for CKD development after HT.
Authors: Michael LoBasso; James Schneider; L Nelson Sanchez-Pinto; Sylvia Del Castillo; Gina Kim; Alysia Flynn; Christine B Sethna Journal: Pediatr Nephrol Date: 2021-08-12 Impact factor: 3.714
Authors: Alia Dani; Nina Price; Karthik Thangappan; Thomas D Ryan; David K Hooper; David S Cooper; David G Lehenbauer; Clifford Chin; Farhan Zafar; David L S Morales Journal: J Thorac Cardiovasc Surg Date: 2022-03-01 Impact factor: 6.439
Authors: Emma H Ulrich; Erin Hessey; Sylvie Perreault; Marc Dorais; Philippe Jouvet; Veronique Phan; Michael Zappitelli Journal: Crit Care Explor Date: 2022-01-18